Reports Q3 revenue $498.8M, consensus $469.92M. “With INGREZZA sales continuing to grow, an expanded indication to treat chorea associated with Huntington’s disease, and positive Phase 3 results in congenital adrenal hyperplasia, Neurocrine remains well positioned to build a leading neuroscience-focused company,” said Kevin Gorman, CEO. “We look forward to sharing more insight into our R&D portfolio and strategy at our December Analyst Day.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
- Neurocrine Biosciences (NBIX) Q3 Earnings Cheat Sheet
- Neurocrine assumed with an Overweight at Cantor Fitzgerald
- Neurocrine price target raised to $143 from $137 at BofA
- Neurocrine price target raised to $135 from $125 at Leerink